Both companies may succeed in this industry.

This biotech has candidates in late-stage clinical development.

Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...

This drugmaker continues to strengthen its investment thesis.

The company got some bad news to start 2026.

In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change lagged the S&P 500's 0.03% gain on the day. Elsewhere, the Dow saw a ...

Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on ...

Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.

Healthcare, retail and finance stocks could do well in 2026. See five picks that experts say could have major upside ...

Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case ...

Shares of GPU titan Nvidia (NASDAQ:NVDA) may have been stuck in a sideways channel for the past six months, but a lot has ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy and hold for 20 years. On January 20, 2026, Guggenheim ...